TO CONDUCT SCREENING EFFORTS (TASK ORDER 5) FOR THE CHEMICAL SCREENING AND OPTIMIZATION FACILITY AND IDENTIFY NEW CHEMICAL MATTER FOR CONTRACEPTION AND REPRODUCTIVE HEALTH RELATED INDICATION

The NICHD has a state-of-the-art Chemical Synthesis and Optimization Facility for advancing both non-hormonal contraceptive and reproductive health related product development. This facility has the capabilities and capacity for preclinical services including Investigational Device Exemption (IDE) or Investigational New Drug (IND)-enabling studies (e.g., protein generation, X-ray crystallography, high throughput screening, structure activity relationships, hit-to-lead generation, drug metabolism). The long-term objective is to enable a preclinical candidate for IND/IDE study(ies) that offers a safe therapeutic option in the field of contraception, and/or reproductive health related indications (pending contractor availability and available funding). Project Number: 75N94023D00006-0-759402500001-1 | Fiscal Year: 2025 | NIH Institute/Center: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Principal Investigator: LEYI GONG | Institution: SRI INTERNATIONAL, MENLO PARK, CA | Award Amount: $352,392 | Activity Code: N01 View on NIH RePORTER: https://reporter.nih.gov/project-details/75N94023D0000607594025000011